Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 12/20 | 0.79 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.73 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.73 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.73 |
| ▸ | MEN1 | O00255 | 1/20 | 0.73 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.73 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.73 |
| ▸ | AR | P10275 | 2/20 | 0.70 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.68 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.68 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.68 |
| ▸ | KARS1 | Q15046 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8785108 | 0.90 | TDP1 (0.72) | TDP1CYP3A4CYP2D6CYP2C19MEN1 | |
| SCHEMBL11817724 | 0.89 | TDP1 (0.82) | TDP1CYP3A4CYP2D6CYP2C19MEN1 | |
| SCHEMBL30265927 | 0.88 | TDP1 (0.72) | TDP1CYP3A4CYP2D6CYP2C19MEN1 | |
| SCHEMBL29975241 | 0.88 | TDP1 (0.79) | TDP1CYP3A4CYP2D6CYP2C19MEN1 | |
| SCHEMBL20856806 | 0.88 | TDP1 (0.82) | TDP1CYP3A4CYP2D6CYP2C19MEN1 | |
| SCHEMBL9112314 | 0.88 | TDP1 (0.82) | TDP1CYP3A4CYP2D6CYP2C19MEN1 | |
| SCHEMBL9107959 | 0.85 | TDP1 (0.78) | TDP1CYP3A4CYP2D6CYP2C19MEN1 | |
| SCHEMBL9109761 | 0.84 | TDP1 (0.76) | TDP1CYP3A4CYP2D6CYP2C19MEN1 | |
| SCHEMBL20874417 | 0.84 | TDP1 (0.76) | TDP1CYP3A4CYP2D6CYP2C19MEN1 | |
| SCHEMBL8884938 | 0.83 | HDAC3 (0.70) | TDP1CYP3A4CYP2D6CYP2C19MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140322304-A1 | COMPOSITIONS AND METHODS RELATING TO PROLIFERATIVE DISEASES | THE PENN STATE RESEARCH FOUNDATION | 2014-10-30 | — | — | US | claimed |
| WO-2012078667-A9 | COMPOSITIONS AND METHODS RELATING TO PROLIFERATIVE DISEASES | THE PENN STATE RESEARCH FOUNDATION (US) | 2012-08-16 | — | — | WO | claimed |
| US-20120141578-A1 | COMPOSITIONS AND METHODS RELATING TO PROLIFERATIVE DISEASES | THE PENN STATE RESEARCH FOUNDATION (US) | 2012-06-07 | — | — | US | claimed |
| US-9839618-B2 | Compositions and methods relating to proliferative diseases | THE PENN STATE RESEARCH FOUNDATION (US) | 2017-12-12 | — | — | US | disclosed |
| US-9839618-B2 | Compositions and methods relating to proliferative diseases | THE PENN STATE RESEARCH FOUNDATION (US) | 2017-12-12 | — | — | US | disclosed |
| US-20170079936-A1 | COMPOSITIONS AND METHODS RELATING TO PROLIFERATIVE DISEASES | THE PENN STATE RESEARCH FOUNDATION | 2017-03-23 | — | — | US | disclosed |
| US-20170079936-A1 | COMPOSITIONS AND METHODS RELATING TO PROLIFERATIVE DISEASES | THE PENN STATE RESEARCH FOUNDATION | 2017-03-23 | — | — | US | disclosed |
| US-9556101-B2 | Compositions and methods relating to proliferative diseases | THE PENN STATE RESEARCH FOUNDATION (US) | 2017-01-31 | — | — | US | disclosed |
| US-9556101-B2 | Compositions and methods relating to proliferative diseases | THE PENN STATE RESEARCH FOUNDATION (US) | 2017-01-31 | — | — | US | disclosed |
| US-20140322304-A1 | COMPOSITIONS AND METHODS RELATING TO PROLIFERATIVE DISEASES | THE PENN STATE RESEARCH FOUNDATION | 2014-10-30 | — | — | US | disclosed |
| US-20140322304-A1 | COMPOSITIONS AND METHODS RELATING TO PROLIFERATIVE DISEASES | THE PENN STATE RESEARCH FOUNDATION | 2014-10-30 | — | — | US | disclosed |
| US-8785502-B2 | Compositions and methods relating to proliferative diseases | THE PENN STATE RESEARCH FOUNDATION (US) | 2014-07-22 | — | — | US | disclosed |
| US-20120141578-A1 | COMPOSITIONS AND METHODS RELATING TO PROLIFERATIVE DISEASES | THE PENN STATE RESEARCH FOUNDATION (US) | 2012-06-07 | — | — | US | disclosed |
| US-20120141578-A1 | COMPOSITIONS AND METHODS RELATING TO PROLIFERATIVE DISEASES | THE PENN STATE RESEARCH FOUNDATION (US) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140322304-A1 | COMPOSITIONS AND METHODS RELATING TO PROLIFERATIVE DISEASES | PCNA, DERA, TOP2A | TDP1 62/4885CYP3A4 4644/4885CYP2D6 3991/4885 |
| US-20120141578-A1 | COMPOSITIONS AND METHODS RELATING TO PROLIFERATIVE DISEASES | PCNA, DERA, TOP2A | TDP1 62/4885CYP3A4 4644/4885CYP2D6 3991/4885 |
| US-20170079936-A1 | COMPOSITIONS AND METHODS RELATING TO PROLIFERATIVE DISEASES | PCNA, DERA, TOP2A | TDP1 62/4885CYP3A4 4644/4885CYP2D6 3991/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.